Recent approaches to intracellular delivery of drugs and DNA and organelle targeting

Annual Review of Biomedical Engineering

Volumn 8, Issue , 2006, Pages 343-375

  Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cell penetrating proteins and peptides; Intracellular antigens; Intracellular drug delivery; Intracellular gene delivery; Liposomes; Lysosomes; Mitochondria; Nuclei; pH sensitive liposomes; Polymeric micelles

Indexed keywords

CELL MEMBRANES; CELLS; CYTOLOGY; DNA; DRUG THERAPY; GENES; PH EFFECTS;

CELL PENETRATING PROTEINS AND PEPTIDES; INTRACELLULAR ANTIGENS; INTRACELLULAR DRUG DELIVERY; INTRACELLULAR GENE DELIVERY; LIPOSOMES; LYSOSOMES; MITOCHONDRIA; NUCLEI; PH SENSITIVE LIPOSOMES; POLYMERIC MICELLES;

DRUG PRODUCTS;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTIBODY; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARGININE; CARRIER PROTEIN; CELL ANTIGEN; CELL RECEPTOR; COMPLEMENTARY DNA; CYTOSKELETON PROTEIN; DNA; DRUG CARRIER; ENZYME; IMMUNOLIPOSOME; LIPID; LIPOFECTIN; LIPOPLEX; LIPOSOME; LYSINE; MACROGOL; MITOCHONDRIAL DNA; PEPTIDE DERIVATIVE; PHOSPHOLIPID DERIVATIVE; PLASMID DNA; POLY(ACRYLATE METHACRYLATE); POLY(N ISOPROPYLACRYLAMIDE); POLYMER; POLYMETHACRYLIC ACID DERIVATIVE; PROTEIN DERIVATIVE; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CELL MEMBRANE PERMEABILITY; CELL NUCLEUS; CELL ORGANELLE; CYTOPLASM; CYTOSOL; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; ENDOCYTOSIS; GENE THERAPY; GENOME; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; NONHUMAN; REVIEW;

ANIMALS; DNA; DRUG DELIVERY SYSTEMS; HUMANS; INTRACELLULAR FLUID; LIPOSOMES; ORGANELLES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; TRANSFECTION;

EID: 33748126226     PISSN: 15239829     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.bioeng.8.061505.095735     Document Type: Review

References (186)

1. Varga CM, Wickham TJ, Lauffenburger DA. 2000. Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol. Bioeng. 70:593-605
2. Chakrabarti R, Wylie DE, Schuster SM. 1989. Transfer of monoclonal antibodies into mammalian cells by electroporation. J. Biol. Chem. 264:15494-500
3. Arnheiter H, Haller O. 1988. Antiviral sTATe against influenza virus neutralized by microinjection of antibodies to interferon-induced Mx proteins. EMBO J. 7:1315-20
4. Straubinger RM, Duzgunes N, Papahadjopoulos D. 1985. pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett. 179:148-54
5. Roth JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, et al. 1998. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin. Oncol. 25(Suppl. 8):33-37
6. Lisziewicz J, Sun D, Lisziewicz A, Gallo RC. 1995. Antitat gene therapy: a candidate for late-stage AIDS patients. Gene Ther. 2:218-22
7. Aalto Setala K, Vuorio E. 1997. Gene therapy of single-gene disorders: preface to the special section. Ann. Med. 29:549-51
8. Farhood H, Serbina N, Huang L. 1995. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim. Biophys. Acta 1235:289-95
9. Scheule RK, St George JA, Bagley RG, Marshall J, Kaplan JM, et al. 1997. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum. Gene Ther. 8:689-707
10. Filion MC, Phililips NC. 1997. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Bhiophys. Acta 1329:345-56
11. Tang F, Hughes JA. 1999. Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. Bioconjug. Chem. 10:791-96
12. Xu Y, Szoka FC Jr. 1996. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35:5616-23
13. Lasic DD. 1993. Liposomes: From Physics to Applications. Amsterdam: Elsevier Sci. Publ. 594 pp.
14. Torchilin VP. 2005. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4:145-60
15. Allen TM, Newman MS, Woodle MC, Mayhew E, Uster PS. 1995. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer 62:199-204
16. Senior JH. 1987. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3:123-93
17. Torchilin VP. 1985. Liposomes as targetable drug carriers. Crit. Rev. Ther. Drug Carriers Syst. 1:65-115
18. Lasic DD, Martin F, eds. 1995. Stealth Liposomes. Boca Raton, FL: CRC Press. 289 pp.
19. Torchilin VP, Narula J, Halpern E, Khaw BA. 1996. Poly(ethylene glycol)coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. Biochim. Biophys. Acta 1279:75-83
20. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL, et al. 2001. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta 1511:397-411
21. Torchilin VP, Weissig V. 2000. Polymeric micelles for the delivery of poorly soluble drugs. In Controlled Drug Delivery: Designing Technologies for the Future, ed. K Park, RJ Mrsny, pp. 297-313. Washington, DC: Am. Chem. Soc.
22. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65:271-84
23. Kwon GS, Kataoka K. 1995. Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 16:295-309
24. Yuan F, Dellian M, Fukumura M, Leunig M, Berk DA, et al. 1995. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55:3752-56
25. Asokan A, Cho MJ. 2002. Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J. Pharm. Sci. 91:903-13
26. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, et al. 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA 84:7413-17
27. Wu GY, Wu CH. 1987. Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. J. Biol. Chem. 262:4429-32
28. Elouahabi A, Ruysschaert JM. 2005. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. 11:336-47
29. Kunath K, von Harpe A, Fischer D, Petersen H, Bickel U, et al. 2003. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control Release 89:113-25
30. Sakurai F, Inoue R, Nishino Y, Okuda A, Matsumoto O, et al. 2000. Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. J. Control Release 66:255-69
31. Labat-Moleur F, Steffan AM, Brisson C, Perron H, Feugeas O, et al. 1996. An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther. 3:1010-17
32. Ogris M, Steinlein P, Carotta S, Brunner S, Wagner E. 2001. DNA/polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSci 3:E21
33. Felgner JH, Kumar R, Sridhar CN, Wheeler CJ, Tsai YJ, et al. 1994. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. Biol. Chem. 269:2550-61
34. Koltover I, Salditt T, Radler JO, Safinya CR. 1998. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281:78-81
35. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, et al. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. USA 92:7297-301
36. 2+ sensitive cytosolic nucleases prevent efficient delivery to the nucleus of injected plasmids. J. Gene Med. 3:153-64
37. Pollard H, Remy JS, Loussouarn G, Demolombe S, Behr JP, Escande D. 1998. Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J. Biol. Chem. 273:7507-11
38. Branden LJ, Mohamed AJ, Smith CI. 1999. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol. 17:784-87
39. Zuhorn IS, Hoekstra D. 2002. On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question? J. Membr. Biol. 189:167-79
40. Torchilin VP, ed. 1991. Immobilized Enzymes in Medicine. Berlin: Springer-Verlag. 206 pp.
41. Torchilin VP, Zhou F, Huang L. 1993. pH-Sensitive liposomes J. Liposome Res. 3:201-55
42. Sheff D. 2004. Endosomes as a route for drug delivery in the real world. Adv. Drug Deliv. Rev. 56:927-30
43. 42a. Leroux JC, ed. 2004. Adv. Drug Deliv. Rev. Vol. 56
44. Asokan A, Cho MJ. 2003. Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. Biochim. Biophys. Acta 1611:151-60
45. Shalaev EY, Steponkus PL. 1999. Phase diagram of 1,2-dioleoyl- phosphatidylethanolamine (DOPE):water system at subzero temperatures and at low water contents. Biochim Biophys Acta 1419:229-47
46. Gaspar M, Perez-Soler R, Cruz ME. 1996. Biological characterization of L-asparaginase liposomal formulations. Cancer Chemother. Pharmacol. 38:373-77
47. Stanimirovic DB, Markovic M, Micic DV, Spatz M, Mrsulja BB. 1994. Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion 'oxidative stress' in gerbil brain. Neurochem. Res. 19:1473-78
48. Lo YL, Tsai JC, Kuo JH. 2004. Liposomes and disaccharides as carriers in spray-dried powder formulations of Superoxide dismutase. J. Control Release. 94:259-72
49. Heeremans JL, Prevost R, Bekkers ME, Los P, Emeis JJ, et al. 1995. Thrombolytic treatment with tissuetype plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA. Thromb. Haemost. 73:488-94
50. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, et al. 1986. Treatment of murine L1210 lymphoid leukemia and melanoma bio with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int. J. Cancer. 37:149-54
51. Fonseca MJ, Jagtenberg JC, Haisma HJ, Storm G. 2003. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharm. Res. 20:423-28
52. Kisel MA, Kulik LN, Tsybovsky IS, Vlasov AP, Vorob'yov MS, et al. 2001. Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in rat. Int. J. Pharm. 216:105-14
53. Geisert EE Jr, Del Mar NA, Owens JL, Holmberg EG. 1995. Transfecting neurons and glia in the rat using pH-sensitive immunoliposomes. Neurosci. Lett. 184:40-43
54. Yessine MA, Leroux JC. 2004. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv. Drug Deliv. Rev. 56:999-1021
55. Chen G, Hoffman AS. 1995. Graft copolymers that exhibit temperature-induced phase transitions over a wide range of pH. Nature 373:49-52
56. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M, Kataoka K. 2005. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug. Chem. 16:122-30
57. Jeong JH, Kim SW, Park TG. 2003. Novel intracellular delivery system of antisense oligonucleotide by self-assembled hybrid micelles composed of DNA/PEG conjugate and cationic fusogenic peptide. Bioconjug. Chem. 14:473-79
58. Lukyanov AN, Hartner WC, Torchilin VP. 2004. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J. Contr. Release 94:187-93
59. Hafez IM, Maurer N, Cullis PR. 2001. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8:1188-96
60. Wang J, Mongayt D, Torchilin VP. 2005. Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J. Drug Target 13:73-80
61. Khaw BA, Torchilin VP, Vural I, Narula J. 1995. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat. Med. 1:1195-98
62. Khaw BA, Vural I, daSilva J, Torchilin VP. 2000. Use of cytoskeleton-specific immunoliposomes for preservation of cell viability and gene delivery. STP Pharma. Sci. 10:279-83
63. Khaw BA, Fallon JT, Beller GA, Haber E. 1979. Specificity of localization of myosin specific antibody fragments in experimental myocardial infarction: histologic, histochemical, autoradiographic and scintigraphic studies. Circulation 60:1527-31
64. Torchilin VP, Khaw BA, Weissig V. 2002. Intracellular targets for DNA delivery: nuclei and mitochondria. Somat. Cell Mol. Genet. 27:49-64
65. Khaw BA, daSilva J, Vural I, Narula J, Torchilin VP. 2001. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J. Control Release. 75:199-210
66. Khaw BA, Scott J, Fallon JT, Haber E, Homey C. 1982. Myocardial injury: quantitation by cell sorting initiated with anti-myosin fluorescent spheres. Science 217:1050-53
67. Torchilin VP, Trubetskoy VS, Milshteyn AM, Canillo J, Wolf GL, et al. 1994. Targeted delivery of diagnostic agents by surface-modified liposomes. J. Control Release 28:45-58
68. Green M, Loewenstein PM. 1988. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT trans-activator protein. Cell 55:1179-88
69. Frankel AD, Pabo CO. 1988. Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 55:1189-93
70. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. 1991. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. USA 88:1864-68
71. Elliott G, O'Hare P. 1997. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88:223-33
72. Schwarze SR, Dowdy SF. 2000. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol. Sci. 21:45-48
73. Lindgren M, Hallbrink M, Prochiantz A, Langel U. 2000. Cell-penetrating peptides. Trends Pharmacol. Sci. 21:99-103
74. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. 2001. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 1515:101-9
75. Mann DA, Frankel AD. 1991. Endocytosis and targeting of exogenous HIV-1 TAT protein. EMBO J. 10:1733-39
76. Schwarze SR, Hruska KA, Dowdy SF. 2000. Protein transduction: unrestricted delivery into all cells? Trends Cell Biol. 10:290-95
77. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, et al. 2001. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276:5836-40
78. Pooga M, Hallbrink M, Zorko M, Langel U. 1998. Cell penetration by transportan. FASEB J. 12:67-77
79. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, et al. 1998. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1414:127-39
80. Mi Z, Mai J, Lu X, Robbins PD. 2000. Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo. Mol. Ther. 2:339-47
81. Gorodetsky R, Levdansky L, Vexler A, Shimeliovich I, Kassis I, et al. 2004. Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C-termini. J. Control. Release 95:477-88
82. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. 1996. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 271:18188-93
83. Sandgren S, Cheng F, Belting M. 2002. Nuclear targeting of macromolecular polyanions by an HIV-TAT derived peptide. Role for cell-surface proteoglycans. J. Biol. Chem. 277:38877-83
84. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. 2003. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278:35109-14
85. Violini S, Sharma V, Prior JL, Dyszlewski M, Piwnica-Worms D. 2002. Evidence for a plasma membrane-mediated permeability barrier to TAT basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry 41:12652-61
86. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J. Biol. Chem. 277:30208-18
87. Caron NJ, Quenneville SP, Tremblay JP. 2004. Endosome disruption enhances the functional nuclear delivery of TAT-fusion proteins. Biochem. Biophys. Res. Commun. 319:12-20
88. Zaro JL, Shen WC. 2003. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Commun. 307:241-47
89. Wadia JS, Stan RV, Dowdy SF. 2004. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10:310-15
90. Wadia JS, Dowdy SF. 2005. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57:579-96
91. Rothbard JB, Jessop TC, Wender PA. 2005. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv. Drug. Deliv. Rev. 57:495-504
92. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, et al. 1994. TAT-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 91:664-68
93. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, et al. 1997. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV TAT peptide. J. Immunol. 159:1666-68
94. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. 1999. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569-72
95. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, et al. 1998. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4:1449-52
96. Brooks H, Lebleu B, Vives E. 2005. TAT peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev. 57:559-77
97. Wheeler DS, Dunsmore KE, Wong HR. 2003. Intracellular delivery of HSP70 using HIV-1 TAT protein transduction domain. Biochem. Biophys. Res. Commun. 301:54-59
98. Yoon HY, Lee SH, Cho SW, Lee JE, Yoon CS, et al. 2002. TAT-mediated delivery of human glutamate dehydrogenase into PC12 cells. Neurochem. Int. 41:37-42
99. Cao G, Pei W, Ge H, Liang Q, Luo Y, et al. 2002. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22:5423-31
100. Asoh S, Ohsawa I, Mori T, Katsura K, Hiraide T, et al. 2002. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. USA 99:17107-12
101. Roeder GE, Parish JL, Stern PL, Gaston K. 2004. Herpes simplex virus VP22-human papillomavirus E2 fusion proteins produced in mammalian or bacterial cells enter mammalian cells and induce apoptotic cell death. Biotechnol. Appl. Biochem. 40(Pt.2):157-65
102. Derer W, Easwaran HP, Leonhardt H, Cardoso MC. 2002. A novel approach to induce cell cycle reentry in terminally differentiated muscle cells. FASEB J. 16:132-33
103. Snyder EL, Dowdy SF. 2001. Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr. Opin. Mol. Ther. 3:147-52
104. Kwon HY, Eum WS, Jang HW, Kang JH, Ryu J, et al. 2000. Transduction of Cu,Zn-superoxide dismutase mediated by an HIV-1 TAT protein basic domain into mammalian cells. FEBS Lett. 485:163-37
105. Jin LH, Bahn JH, Eum WS, Kwon HY, Jang SH, et al. 2001. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radic. Biol. Med. 31:1509-19
106. Yang Y, Ma J, Song Z, Wu M. 2002. HIV-1 TAT-mediated protein transduction and subcellular localization using novel expression vectors. FEBS Lett. 532:36-44
107. Eguchi A, Akuta T, Okuyama H, Senda T, Yokoi H, et al. 2001. Protein transduction domain of HIV-1 TAT protein promotes efficient delivery of DNA into mammalian cells. J. Biol. Chem. 276:26204-10
108. Derossi D, Chassaing G, Prochiantz A. 1998. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8:84-87
109. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. 2003. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 278:11411-18
110. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, et al. 2003. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 TAT protein are transferred to mammalian cells by endocytosis-mediated pathways. J. Biol. Chem. 278:42625-36
111. Tasciotti E, Zoppe M, Giacca M. 2003. Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 TAT. Cancer Gene Ther. 10:64-74
112. Suzuki K, Murtuza B, Brand NJ, Varela-Carver A, Fukushima S, Yacoub MH. 2004. Enhanced effect of myocardial gene transfection by VP22-mediated intercellular protein transport. J. Mol. Cell. Cardiol. 36:603-6
113. Zavaglia D, Normand N, Brewis N, O'Hare P, Favrot MC, Coll JL. 2003. VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice. Mol. Ther. 8:840-45
114. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, et al. 1998. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:857-61
115. Anderson AD, Nichols E, Manger R, Woodle D, Barry M, Fritzberg AR. 1993. Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV TAT protein-derived peptide. Biochem. Biophys. Res. Commun. 194:876-84
116. Stein S, Weiss A, Adermann K, Lazarovici P, Hochman J, Wellhoner H. 1999. A disulfide conjugate between anti-tetanus antibodies and HIV (37-72)TAT neutralizes tetanus toxin inside chromaffin cells. FEBS Lett. 458:383-86
117. Nori A, Jensen KD, Tijerina M, Kopeckova P, Kopecek J. 2003. Subcellular trafficking of HPMA copolymer-TAT conjugates in human ovarian carcinoma cells. J. Control Release 91:53-59
118. Jo D, Liu D, Yao S, Collins RD, Hawiger J. 2005. Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis. Nat. Med. 11:892-98
119. Josephson L, Tung CH, Moore A, Weissleder R. 1999. High-efficiency intracellular magnetic labeling with novel superparamagnetic-TAT peptide conjugates. Bioconjug. Chem. 10:186-91
120. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, et al. 2000. TAT peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18:410-14
121. Dodd CH, Hsu HC, Chu WJ, Yang P, Zhang HG, et al. 2001. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide-derived superparamagnetic nanoparticles. J. Immunol. Methods 256:89-105
122. Zhao M, Kircher MF, Josephson L, Weissleder R. 2002. Differential conjugation of TAT peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 13:840-44
123. Tkachenko AG, Xie H, Liu Y, Coleman D, Ryan J, et al. 2004. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug. Chem. 15:482-90
124. Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, et al. 2005. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 11:678-82
125. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. 2001. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA 98:8786-91
126. Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. 2004. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim. Biophys. Acta 1665:48-56
127. Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA. 2004. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol. Life Sci. 61:1785-94
128. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B, D'Souza GG. 2003. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc. Natl. Acad. Sci. USA 100:1972-77
129. Torchilin VP, Levchenko TS. 2003. TAT-liposomes: a novel intracellular drug carrier. Curr. Protein Pept. Sci. 4:133-40
130. Tseng YL, Liu JJ, Hong RL 2002. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and TAT: a kinetic and efficacy study. Mol. Pharmacol. 62:864-72
131. Costantini P, Jacotot E, Decaudin D, Kroemer G. 2000. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. 92:1042-53
132. Reed JC. 1999. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:2941-53
133. Preston TJ, Abadi A, Wilson L, Singh G. 2001. Mitochondrial contributions to cancer cell physiology: potential for drug development. Adv. Drug Deliv. Rev. 49:45-61
134. Wallace DC. 1999. Mitochondrial diseases in man and mouse. Science 283:1482-88
135. Holt IJ, Harding AE, Morgan-Hughes JA. 1988. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 331:717-19
136. Harding AE. 1991. Neurological disease and mitochondrial genes. TINS 14:132-38
137. Sperl W. 1997. Diagnose und Therapie von Mitochondriopathien. Wien. Klin. Wochenschr. 109:93-99
138. Kagava A, Inoki Y, Endo H. 2001. Gene therapy by mitochondria transfer. Adv. Drug Deliv. Rev. 49:107-20
139. D'Souza GG, Weissig V. 2004. Approaches to mitochondrial gene therapy. Curr. Gene Ther. 4:317-28
140. Butow RT, Fox TD. 1990. Organelle transformation: shoot first, ask questions later. Trends Biochem. Sci. 15:465-68
141. Collombet JM, Wheeler VC, Vogel F, Coutelle C. 1997. Introduction of plasmid DNA into isolated mitochondria by electroporation. A novel approach towards gene correction for mitochondrial disorders. J. Biol. Chem. 272:5342-47
142. Kagawa Y, Hayashi JI. 1997. Gene therapy of mitochondrial diseases using human cytoplasts. Gene Ther. 4:6-10
143. Seibel P, Trappe J, Villani G, Klopstock T, Papa S, Reichman H. 1995. Transfection of mitochondria: strategy towards a gene therapy of mitochondrial DNA diseases. Nucleic Acid Res. 23:10-17
144. Vestweber D, Schatz G. 1989. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature (London) 338:170-72
145. Zabner J, Fasbender AJ, Moninger T, Poellinger A, Welsh MJ. 1995. Cellular and molecular barriers to gene transfer by a cationic lipid. J. Biol. Chem. 270:18997-9007
146. Murphy MP. 1989. Slip and leak in mitochondrial oxidative phosphorylation. Biochim. Biophys. Acta 977:123-41
147. Weissig V, Torchilin VP. 2001. Cationic bolasomes with delocalized charge centers as mitochondria-specific DNA delivery systems. Adv. Drug Deliv. Rev. 49:127-49
148. Chen LB, Summerhayes IC, Johnson LV, Walsh ML, Bernal SD, Lampidis TJ. 1982. Probing mitochondria in living cells with rhodamine 123. Cold Spring Harb. Symp. Quant. Biol. 46:141-55
149. Rideout D, Bustamante A, Patel J. 1994. Mechanism of inhibition of FaDu hypopharyngeal carcinoma cell growth by tetraphenylphosphonium chloride. Int. J. Cancer 57:247-53
150. Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J. 1998. DQAsomes: a novel potential drug and gene delivery system made from dequalinium™. Pharm. Res. 15:334-37
151. Weissig V, Torchilin VP. 2000. Mitochondriotropic cationis vesicles: a strategy towards mitochondrial gene therapy. Current Pharm. Biotech. 1:325-46
152. Lasch J. 1999. Bolaamphiphile dequalinium™ vesicles and their stable complexes with DNA which are protected from Dnase attack. Biol. Chem. 380:647-52
153. D'Souza GG, Rammohan R, Cheng SM, Torchilin VP, Weissig V. 2003. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 92:189-97
154. Holmuhamedov E, Lewis L, Bienengraeber M, Holmuhamedova M, Jahangir A, Terzic A. 2002. Suppression of human tumor cell proliferation through mitochondrial targeting. FASEB J. 16:1010-16
155. Foley S, Crowley C, Smaihi M, Bonfils C, Erlanger BF, et al. 2002. Cellular localisation of a water-soluble fullerene derivative. Biochem. Biophys. Res. Commun. 294:116-19
156. Del Gaizo V, MacKenzie JA, Payne RM. 2003. Targeting proteins to mitochondria using TAT. Mol. Genet. Metab. 80:170-80
157. Torchilin VP. 1991. Immobilized Enzymes in Medicine. Berlin: Springer-Verlag
158. Wolf M, Ransberger K. 1972. Enzyme Therapy. New York: Vantage Press
159. Tager JM, Daems WT, Hoodhwinkel GJM, ed. 1974. Enzyme Therapy in Lysosomal Storage Diseases. Amsterdam: North/Holland
160. Grabowsky GA, Desnick RJ. 1981. Enzyme replacement in genetic diseases. In Enzymes as Drugs, ed. JS Holcenberg, J Roberts. New York: Wiley. 167 pp.
161. Connor J, Huang L. 1986. pH-sensitive immunoliposonies as an efficient and target-specific carrier for antitumor drugs. Cancer Res. 46:3431-35
162. Desnick RJ, Thorpe SR, Fidler MB. 1976. Toward enzyme therapy for lysosomal storage diseases. Physiol. Rev. 56:57-99
163. Johnson WG, Desnick RJ, Long DM, Sharp HL, Krivit W, et al. 1973. Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. In Enzyme Therapy in Genetic Diseases, ed. D Bergsma, 9:120. Baltimore: William and Wilkins
164. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. 1974. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med. 291:989-93
165. Brady RO, Tallman JF, Johnson WG, Gal AE, Leahy WR, et al. 1973. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry's disease. N. Engl. J. Med. 289:9-14
166. Gregoriadis G. 1978. Liposomes in the therapy of lysosomal storage diseases. Nature 275:695-96
167. Gregoriadis G, Dean MF. 1979. Enzyme therapy in genetic diseases. Nature 278:603-4
168. Gregoriadis G, Ryman BL. 1972. Lysosomal localization of β-fructofuranosidase-containing liposomes injected into rats. Biochem. J. 129:123-33
169. Patel HM, Ryman BE. 1974 α-Mannosidase in zinc-deficient rats. Possibility of liposomal therapy in mannosidosis. Biochem. Soc. Trans. 2:1014-16
170. Gregoriadis G, Putman D, Louis L, Neerunjun D. 1974. Comparative effect and fate of non-entrapped and liposome-entrapped neuraminidase injected into rats. Biochem. J. 140:323-30
171. Steger LD, Desnick RJ. 1977. Enzyme therapy. VI. Comparative in vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. Biochim. Biophys. Acta 464:530-46
172. Colley CM, Ryman BE. 1976. The use of a liposomally entrapped enzyme in the treatment of an artificial storage condition. Biochim. Biophys. Acta 451:417-25
173. Reynolds GC, Baker HJ, Reynolds RH. 1978. Enzyme replacement using liposome carriers in feline Gm1 gangliosidosis fibroblasts. Nature 275:754-55
174. Das PK,Murray GJ, Zirzow GC, Brady RO, Barranger JA. 1985. Lectin-specific targeting of β-glucocerebrosidase to different liver cells via glycosylated liposomes. Biochem. Med. 33:124-33
175. Umezawa F, Eto Y, Tokoro T, Ito F, Maekawa K. 1985. Enzyme replacement with liposomes containing beta-galactosidase from Charonia lumpas in murine globoid cell leukodysirophy (Twitcher). Biochem. Biophys. Res. Commun. 127:663-63
176. Espinola LG, Wider EV, Stella AM, Del C, Battle AM. 1983. Enzyme replacement therapy in porphyriasis-II: entrapment of δ-aminolaevulinate dehydratase in liposomes. Int. J. Biochem. 15:439-45
177. Belchetz PE, Crawley JC, Braidman IP, Gregoriadis G. 1977. Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: β-glucosidase. Lancet 8020:116-17
178. Rouille Y, Rohn W, Hoflack B. 2000. Targeting of lysosomal proteins. Semin. Cell Dev. Biol. 11:165-71
179. Lloyd JB. 2000. Lysosome membrane permeability: implications for drug delivery. Adv. Drug Deliv. Rev. 41:189-200
180. Bathori G, Cervenak L, Karadi I. 2004. Caveolae-an alternative endocytotic pathway for targeted drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 21:67-95
181. Helms JB, Zurzolo C. 2004. Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic 5:247-54
182. Hogset A, Prasmickaite L, Selbo PK, Helium M, Engesaeter BO, et al. 2004. Photochemical internalisation in drug and gene delivery. Adv. Drug. Deliv. Rev. 56:95-115
183. Ciechanover A. 2003. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem. Soc. Trans. 31:474-81
184. Jensen KD, Nori A, Tijerina M, Kopeckova P, Kopecek J. 2003. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J. Control Release 87:89-105
185. Moyer BD, Balch WE. 2001. A new frontier in pharmacology: the endoplasmic reticulum as a regulated export pathway in health and disease. Expert. Opin. Ther. Targets 5:165-76
186. Costin GE, Trif M, Nichita N, Dwek RA, Petrescu SM. 2002. pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cells. Biochem. Biophys. Res. Commun. 293:918-23